Comparison of effects of metformin and inositol on AMH levels in PCOS patients

Anurag Chaudhary; Manju Khemani; Bela Makhija; Kiranjeet Kaur

doi:10.18203/2320-1770.ijrcog20263432

Authors

Anurag Chaudhary Department of Obstetrics and Gynecology, Max Smart Super Specialty Hospital, Saket, New Delhi, India
Manju Khemani Department of Obstetrics and Gynecology, Max Smart Super Specialty Hospital, Saket, New Delhi, India
Bela Makhija Department of Obstetrics and Gynecology, Max Smart Super Specialty Hospital, Saket, New Delhi, India
Kiranjeet Kaur Department of Obstetrics and Gynecology, Max Smart Super Specialty Hospital, Saket, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263432

Keywords:

AMH, Inositol, Metformin, PCOS

Abstract

Background: PCOS is very common problem. Insulin resistance is an integral part of PCOS. AMH level in women with PCOS are 2-3 times higher than in healthy women. In PCOS patients, there is excess amount of AMH and its physiological effect lasts longer than it should in larger follicles, leads to arrest of dominant follicle selection.

Methods: It was a prospective, interventional randomized clinical trial, a single tertiary center study over a period of 8 months. Cases with the documented PCOS were taken into account and divided into 2 groups, group A and group B randomly by alternate assigning of patients. Group A was given metformin and group B was given inositol. Group A was given metformin 850 mg twice daily orally and group B was given myo-inositol 1100 mg +D chiro inositol 27.6 mg plus 100 pg folic acid once daily for 12 weeks.

Results: AMH levels were reassessed after 12 weeks of period and changes in the levels of AMH were compared. In metformin group total number of patients were 86 of which 84 patients (97.7%) showed decrease in AMH levels while 2 patients (2.33%) did not show any changes. In inositol group total number of patients were 87 of which 53 patients (60.91%) showed decrease in AMH levels while 34 patients (39.1%) did not show any changes. There was a significant difference between the groups in terms of distribution of decrease in AMH (χ²=35.454, p<0.001).

Conclusions: As compared to Inositol group there were more patients who had decrease in AMH levels in metformin group. Hence, metformin is better than inositol in decreasing AMH levels in PCOS patients.

References

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Bhide P, Homburg R. Anti-Müllerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:38-45.

Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod. 2009;24(11):2917-23.

Majid H, Masood Q, Khan AH. Homeostatic model assessment for insulin resistance (HOMA-IR): a better marker for evaluating insulin resistance than fasting insulin in women with polycystic ovarian syndrome. J Coll Phys Surg Pak. 2017;27(3):123-6.

Madsen HN, Lauszus FF, Trolle B, Ingerslev HJ, Tørring N. Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand. 2015;94:547-51.

Neagu M, Cristescu C. Anti-Műllerian hormone- a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012;15:462-4.

Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, et al. Metformin versus myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol. 2017;86(5):725-30.

Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017;2(33):39-42.

Nehra J, Kaushal J, Singhal SR, Ghalaut VS. Comparison of myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Int J Pharm Pharm Sci. 2017;27:144.

Angik R. A comparative study of metabolic and hormonal effects of myoinositol vs metformin in women with polycystic ovary syndrome: a randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2015;1.

Grigoryan O, Absatarova J, Andreeva E, Melnichenko G, Dedov I. Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol. 2014;66(1):85-9.

Sheriba N, Abdelsalam M, Mostafa B, Mamdouh M, Eltohamy S. Anti-Mullerian hormone, a marker for metformin therapy efficacy in polycystic ovarian syndrome: a pilot study on an Egyptian population. Egypt J Obes Diabetes Endocrinol. 2017;3:68.

Nascimento AD, Lara LAS, Rosa-e-Silva ACJ de S, Ferriani RA, Reis RM, Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29:246-9.

Foroozanfard F, Samimi M, Hosseini Almadani K, Sehat M. Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Phys. 2017;25:5969-73.

Jaura S, Kaur I, Singh J, Madan A. A prospective study of metformin versus myoinositol plus d-chiro inositol combination therapy in polycystic ovarian syndrome. Int J Basic Clin Pharmacol. 2020;24:276-81.

Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019;35(5):406-11.

Bahadur A, Arora H, Ravi AK, Naithani M, Bahurupi Y, Chaturvedi J, et al. Comparison of clinical, metabolic and hormonal effects of metformin versus combined therapy of metformin with myoinositol plus D-chiro-inositol in women with polycystic ovary syndrome (PCOS): a randomized controlled trial. Cureus. 2021;13(6).

Zeng L, Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;59:30-8.